Quality and Outcomes of Treatment of Hypercalcemia of Malignancy

Cancer Invest. 2015;33(8):331-9. doi: 10.3109/07357907.2015.1047506. Epub 2015 Jun 12.

Abstract

Using a nationwide database, 4,874 patients with hypercalcemia of malignancy were identified. The in-hospital mortality rate was 6.8%. Overall, 1,971 (40.4%) patients received pamidronate and 1,399 (28.7%) received zoledronic acid during hospitalization. Calcitonin was utilized in 1,337 (27.4%) patients while glucocorticoids were administered to 1,311 (26.9%). Use of contraindicated medications was noted in 136 (2.8%) patients who received thiazide diuretics and 12 (0.2%) who received lithium. Tumor site, presence of bone metastases, and severity of illness were predictors of treatment. There was no association between treatment with bisphosphonates, calcitonin, or glucocorticoids and morbidity or mortality.

Keywords: Calcium; Hypercalcemia; Malignancy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Calcitonin / therapeutic use
  • Diphosphonates / therapeutic use
  • Diuretics / therapeutic use
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology
  • Hypercalcemia / mortality
  • Imidazoles / therapeutic use
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasms / complications*
  • Neoplasms / drug therapy
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Pamidronate
  • Quality of Health Care
  • Treatment Outcome
  • Zoledronic Acid

Substances

  • Diphosphonates
  • Diuretics
  • Glucocorticoids
  • Imidazoles
  • Zoledronic Acid
  • Calcitonin
  • Pamidronate